Clinical trial of Wistar Institute 17-1A monoclonal antibody in patients with advanced gastrointestinal adenocarcinoma: a preliminary report.
Clinical trial of Wistar Institute 17-1A monoclonal antibody in patients with advanced gastrointestinal adenocarcinoma: a preliminary report.
复制标题
Wistar Institute 17-1A 单克隆抗体在晚期胃肠道腺癌患者中的临床试验：初步报告。
作者：
H. Verrill;M. Goldberg;R. Rosenbaum;R. Abbott;L. Simunovic;Z. Steplewski;H. Koprowski
应用17-1A单抗对22例转移性胃肠道癌患者进行免疫治疗。治疗标准包括晚期结肠癌、胃癌或胰腺癌的客观证据(CAT扫描或X光阳性，肿瘤标志物升高，和/或肝功能测试异常)。所有病例的肿瘤组织抗原性均为阳性。绩效状态从50%到100%不等。未发现不良反应。在接受治疗的22例患者中，4例(18%)死亡，没有快速进展的疾病，4例(18%)缓慢进展的疾病，10例(45%)病情稳定，没有一例被认为是部分或完全缓解。现在对4例患者的反应进行分类还为时过早。在有抗独特型数据的8名患者中，有6名患者死亡或疾病进展与阴性抗独特型反应相关，临床稳定性与阳性抗独特型反应相关。在被认为是稳定的患者中，从治疗前血清19-9浓度到当前值的百分比变化范围从-10%到+353%。在已经死亡或已经被归类为缓慢进展的患者中，血清19-9的变化从+13%到+707%不等。
Immunotherapy using monoclonal antibody 17-1A has been performed on 22 patients with metastatic gastrointestinal cancer. Criteria for treatment included objective evidence of advanced colon, gastric, or pancreatic cancer (positive CAT scan or x-rays, elevated tumor markers, and/or abnormal liver function tests). The tumor tissue was antigenically positive in all cases. Performance status ranged from 50 to 100%. No adverse reactions were noted. Of the 22 cases treated, 4 (18%) have died, none have rapidly progressive disease, 4 (18%) have slowly progressive disease, 10 (45%) are considered stable with disease, and none are considered partial or complete responses. It is too early to classify the response in 4 cases. In 6 of 8 patients where anti-idiotypic data was available, death or progressive disease was correlated to negative anti-idiotypic response, and clinical stability to a positive anti-idiotypic response. In the patients considered to be stable, the percent change from pre-treatment serum 19-9 concentrations to current values ranged from -10% to +353%. In the patients who have died or have been classified as slowly progressive the serum 19-9 changes ranged from +13% to +707%.